Phase 2B trial for PP405 leaked (The study Pelage DOESN'T want you to see)

Concise summary

A leaked report from a completed Phase 2B (3‑month extension for a total of 6 months) trial of topical “PP405” (Polage Pharmaceuticals) shows the placebo/vehicle outperformed the active treatment. The leak contradicts earlier optimistic hype and suggests PP405 is unlikely to be a major hair‑regrowth breakthrough.

Study design and key results (Phase 2B extension)

• Design

  • Double‑blind extension of the original Phase 2A trial (initial 3 months + 3‑month extension = 6 months total).
  • Participants remained blinded and continued on the same topical (active or placebo) as in Phase 2A.

• Subjects

  • 66 total participants: 40 on topical PP405, 26 on topical placebo.

• Primary endpoint

  • Change in total hair counts (hairs per cm²).

• Results

  • PP405 group: +5.1 hairs/cm² at 6 months (p = 0.049) — marginally significant versus baseline.
  • Placebo group: +33.7 hairs/cm² at 6 months (p < 0.00001) — large within‑group increase.
  • Between‑group comparison: placebo exceeded PP405 by 28.4 hairs/cm² (p < 1e‑7) — highly significant favoring placebo.
  • Note: the published slide/table from Polage was redacted; the presenter’s talk at the conference reportedly rehashed earlier Phase 2A material and omitted these Phase 2B details.

Scientific concepts, observations, and implications

• Trial structure

  • A Phase 2A followed by a blinded Phase 2B extension was used to assess longer‑term effects.

• Placebo/vehicle effects

  • The large hair‑count increase in the placebo arm suggests a potent vehicle/placebo effect or other non‑drug factors affecting hair counts in this study.

• Statistics and interpretation

  • The active arm showed a small absolute improvement with a borderline p‑value versus baseline, while the placebo arm showed a much stronger response, producing a highly significant advantage for placebo in between‑group comparison.
  • This pattern implies either PP405 is ineffective relative to vehicle or, less likely but possible, PP405 may inhibit the vehicle’s beneficial effect.

• Verification efforts

  • Investigators reportedly tested the placebo vehicle for contamination (e.g., minoxidil/finasteride) and reported finding nothing unusual — the placebo was said to be the same vehicle without PP405.

• Practical implication

  • Presenters emphasized that established, evidence‑backed therapies (5α‑reductase inhibitors such as finasteride/dutasteride and topical minoxidil) remain the reliable standard of care. Pipeline drugs should not replace proven treatments without robust positive data.

Other trial and industry notes

• The presenter at the conference had previously presented Phase 2A results; Phase 2B results were tightly guarded by Polage and later leaked.
• Community speculation included ideas of industrial sabotage, but reported analyses did not support contamination of the vehicle.
• Anecdotal/rumored company reaction: severe disappointment on unblinding; tongue‑in‑cheek claims that Polage might reposition or rename their vehicle in future trials (unverified).
• Planned next steps: Polage reportedly plans further trials (Phase 3 was suggested), but specifics and official presentation dates were not provided in the leak.

Limitations and caveats

• The Polage slide was redacted; the Phase 2B account is based on a leak and an informant (a co‑investigator who requested anonymity).
• Interpretation depends on accurate reporting of the leaked numbers. Until Polage or a peer‑reviewed report publishes full data, these results should be treated cautiously.

Researchers and sources featured

• Dr. Arash Mostaghimi — presenter of Phase 2A results (affiliated with Harvard as referenced in the video).
• Unnamed Harvard co‑investigator / whistleblower (requested anonymity).
• Polage Pharmaceuticals — developer of PP405.
• Amplifica — company mentioned (developing AMP‑303; referenced in speculation).
• American Academy of Dermatology (AAD) — venue of the presentation (annual dermatology meeting).
• Reddit and online patient/community discussions — community sources referenced.